Mar 15, 2024 8:00am EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 21, 2024 8:00am EST Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Feb 15, 2024 8:00am EST Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Feb 13, 2024 8:00am EST Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Feb 06, 2024 8:00am EST Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Jan 31, 2024 8:00am EST Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Jan 25, 2024 8:00am EST Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
Jan 23, 2024 8:00am EST Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR